Literature DB >> 22265889

Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output.

Megan L Fitzgerald1, Eli Shobin, Virginia M Pickel.   

Abstract

Cannabinoid modulation of dopaminergic transmission is suggested by the ability of delta9-tetrahydrocanabinoid to affect motor and motivated behaviors in a manner similar to that produced by pharmacological manipulation of the nigrostriatal and mesocorticolimbic dopamine systems. These behavioral effects as well as analogous effects of endocannabinoids are largely mediated through the cannabinoid type 1 receptor (CB1R). This receptor is located within the substantia nigra and ventral tegmental area, which respectively house the somata of nigrostriatal and mesocorticolimbic dopaminergic neurons. The CB1R is also abundantly expressed in brain regions targeted by the efferent terminals of these dopaminergic neurons. In this review we present the accumulating anatomical and electrophysiological evidence indicating that in each of these systems cannabinoids modulate dopamine transmission largely if not exclusively through indirect mechanisms. The summarized mechanisms include presynaptic release of amino acid transmitters onto midbrain dopamine neurons and onto both cortical and striatal neurons that express dopamine D1-like or D2-like receptors functionally affiliated with the CB1 receptor. The review concludes with a consideration of the psychiatric and neurological implications of cannabinoid modulation of dopamine transmission within these networks.
Copyright © 2011. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22265889      PMCID: PMC3389172          DOI: 10.1016/j.pnpbp.2011.12.004

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  88 in total

1.  Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons.

Authors:  I Katona; B Sperlágh; A Sík; A Käfalvi; E S Vizi; K Mackie; T F Freund
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

2.  CB1 cannabinoid receptors are enriched in the perisynaptic annulus and on preterminal segments of hippocampal GABAergic axons.

Authors:  G Nyíri; C Cserép; E Szabadits; K Mackie; T F Freund
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

3.  Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types.

Authors:  Agnes L Bodor; István Katona; Gábor Nyíri; Ken Mackie; Catherine Ledent; Norbert Hájos; Tamás F Freund
Journal:  J Neurosci       Date:  2005-07-20       Impact factor: 6.167

4.  Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?

Authors:  Christopher S Kearn; Katherine Blake-Palmer; Emma Daniel; Ken Mackie; Michelle Glass
Journal:  Mol Pharmacol       Date:  2005-02-14       Impact factor: 4.436

5.  Independent presynaptic and postsynaptic mechanisms regulate endocannabinoid signaling at multiple synapses in the ventral tegmental area.

Authors:  Arthur C Riegel; Carl R Lupica
Journal:  J Neurosci       Date:  2004-12-08       Impact factor: 6.167

Review 6.  Cortical inhibitory neurons and schizophrenia.

Authors:  David A Lewis; Takanori Hashimoto; David W Volk
Journal:  Nat Rev Neurosci       Date:  2005-04       Impact factor: 34.870

7.  Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons.

Authors:  Miriam Melis; Simona Perra; Anna Lisa Muntoni; Giuliano Pillolla; Beat Lutz; Giovanni Marsicano; Vincenzo Di Marzo; Gian Luigi Gessa; Marco Pistis
Journal:  J Neurosci       Date:  2004-11-24       Impact factor: 6.167

Review 8.  Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.

Authors:  Carl R Lupica; Arthur C Riegel
Journal:  Neuropharmacology       Date:  2005-06       Impact factor: 5.250

9.  Dopamine affects parvalbumin expression during cortical development in vitro.

Authors:  L L Porter; E Rizzo; J P Hornung
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

10.  Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice.

Authors:  H Steiner; T I Bonner; A M Zimmer; S T Kitai; A Zimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

View more
  29 in total

1.  Cannabinoids Stimulate the TRP Channel-Dependent Release of Both Serotonin and Dopamine to Modulate Behavior in C. elegans.

Authors:  Mitchell Oakes; Wen Jing Law; Richard Komuniecki
Journal:  J Neurosci       Date:  2019-03-18       Impact factor: 6.167

2.  Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.

Authors:  B A S Reyes; A F Carvalho; P Szot; D J Kalamarides; Q Wang; L G Kirby; E J Van Bockstaele
Journal:  Exp Neurol       Date:  2017-03-21       Impact factor: 5.330

Review 3.  Reward-centricity and attenuated aversions: An adolescent phenotype emerging from studies in laboratory animals.

Authors:  Tamara L Doremus-Fitzwater; Linda P Spear
Journal:  Neurosci Biobehav Rev       Date:  2016-08-11       Impact factor: 8.989

4.  Cannabinoid modulation of alpha2 adrenergic receptor function in rodent medial prefrontal cortex.

Authors:  Alessandra M Cathel; Beverly A S Reyes; Qin Wang; Jonathan Palma; Kenneth Mackie; Elisabeth J Van Bockstaele; Lynn G Kirby
Journal:  Eur J Neurosci       Date:  2014-08-18       Impact factor: 3.386

5.  Role of Dopamine Type 1 Receptors and Dopamine- and cAMP-Regulated Phosphoprotein Mr 32 kDa in Δ9-Tetrahydrocannabinol-Mediated Induction of ΔFosB in the Mouse Forebrain.

Authors:  Matthew F Lazenka; Aaron J Tomarchio; Aron H Lichtman; Paul Greengard; Marc Flajolet; Dana E Selley; Laura J Sim-Selley
Journal:  J Pharmacol Exp Ther       Date:  2015-06-22       Impact factor: 4.030

6.  Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Authors:  Matthew F Lazenka; Bethany G David; Aron H Lichtman; Eric J Nestler; Dana E Selley; Laura J Sim-Selley
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

Review 7.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

8.  The impact of adolescent social isolation on dopamine D2 and cannabinoid CB1 receptors in the adult rat prefrontal cortex.

Authors:  M L Fitzgerald; K Mackie; V M Pickel
Journal:  Neuroscience       Date:  2013-01-16       Impact factor: 3.590

9.  Haloperidol and rimonabant increase delay discounting in rats fed high-fat and standard-chow diets.

Authors:  Steven R Boomhower; Erin B Rasmussen
Journal:  Behav Pharmacol       Date:  2014-12       Impact factor: 2.293

Review 10.  Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.

Authors:  Christopher D Verrico; Colin N Haile; Thomas F Newton; Thomas R Kosten; Richard De La Garza; Richard De La Garza
Journal:  Expert Opin Investig Drugs       Date:  2013-09-14       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.